检索结果-南通市图书馆

Peptic ulcer disease in non-alcoholic fatty liver disease hospitalizations:A new challenge on the horizon in the United States

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Hepatology 2023年第4期15卷 564-576页

作者： Dushyant Singh Dahiya Vinay Jahagirdar Hassam Ali Manesh Kumar Gangwani Muhammad Aziz Saurabh Chandan Amandeep Singh Abhilash Perisetti Aakriti Soni Sumant Inamdar Madhusudhan R Sanaka Mohammad Al-Haddad Department of Internal Medicine Central Michigan University College of MedicineSaginawMI 48601United States Department of Internal Medicine University of Missouri-Kansas CityKansas CityMO 64110United States Department of Internal Medicine East Carolina UniversityGreenvilleNC 27858United States Department of Internal Medicine The University of ToledoToledoOH 43606United States Department of Gastroenterology The University of ToledoToledoOH 43606United States Division of Gastroenterology and Hepatology CHI Creighton University Medical CenterOmahaNE 68131United States Department of Gastroenterology Hepatology and NutritionCleveland Clinic FoundationClevelandOH 44195United States Division of Gastroenterology and Hepatology Kansas City Veterans Affairs Medical CenterKansas CityMO 64128United States Department of Internal Medicine Saint Vincent HospitalWorcesterMA 01608United States Division of Gastroenterology and Hepatology University of Arkansas for Medical SciencesLittle RockAR 72205United States Division of Gastroenterology and Hepatology Indiana University School of MedicineIndianapolisIN 46202United States

BACKGROUND Peptic ulcer disease(PUD)is frequently seen in patients with liver ***,current literature lacks data on PUD in non-alcoholic fatty liver disease(NAFLD)*** To identify trends and clinical outcomes of PUD in NAFLD hospitalizations in the United *** The National Inpatient Sample was utilized to identify all adult(≥18 years old)NAFLD hospitalizations with PUD in the United States from *** trends and outcomes were ***,a control group of adult PUD hospitalizations without NAFLD was also identified for a comparative analysis to assess the influence of NAFLD on *** The total number of NAFLD hospitalizations with PUD increased from 3745 in 2009 to 3805 in *** noted an increase in the mean age for the study population from 56 years in 2009 to 63 years in 2019(Pnon-NAFLD PUD *** of the gastrointestinal tract,coagulopathy,alcohol abuse,malnutrition,and fluid and electrolyte disorders were identified to be independent predictors of inpatient mortality for NAFLD hospitalizations with *** Inpatient mortality for NAFLD hospitalizations with PUD increased for the study ***,there was a significant decline

关键词： non-alcoholic fatty liver disease Peptic ulcer disease Trends Outcomes Mortality

Rodent models and metabolomics in non-alcoholic fatty liver disease: What can we learn?

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Hepatology 2022年第2期14卷 304-318页

作者： Maria Martin-Grau Vannina G Marrachelli Daniel Monleon Department of Pathology University of ValenciaValencia 46010Spain Department of Physiology University of ValenciaValencia 46010Spain Health Research Institute INCLIVA Valencia 46010Spain CIBER de Fragilidad y Envejecimiento Saludable(CIBERfes) Madrid 28029Spain

non-alcoholic fatty liver disease(NAFLD)prevalence has increased drastically in recent decades,affecting up to 25%of the world’s *** is a spectrum of different diseases that starts with asymptomatic steatosis and continues with development of an inflammatory response called steatohepatitis,which can progress to *** molecular and metabolic changes are required for the hepatocyte to finally vary its function;hence a“multiple hit”hypothesis seems a more accurate *** studies and current knowledge suggest that in most cases,NAFLD initiates and progresses through most of nine hallmarks of the disease,although the triggers and mechanisms for these can vary *** use of animal models remains crucial for understanding the disease and for developing tools based on biological *** certain requirements to be met,a good model must imitate certain aspects of the human NAFLD disorder,be reliable and reproducible,have low mortality,and be compatible with a simple and feasible *** studies in these models provides a direct reflection of the workings of the cell and may be a useful approach to better understand the initiation and progression of the *** seems a valid tool for studying metabolic pathways and crosstalk between organs affected in animal models of NAFLD and for the discovery and validation of relevant biomarkers with biological *** this review,we provide a brief introduction to NAFLD hallmarks,the five groups of animal models available for studying NAFLD and the potential role of metabolomics in the study of experimental NAFLD.

关键词： non-alcoholic fatty liver disease liver disease Rodent models Metabolic profiling Metabolomics Biomarkers

Growing challenge of post-liver transplantation non-alcoholic fatty liver disease

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Transplantation 2022年第9期12卷 281-287页

作者： Maria Styliani Kalogirou Olga Giouleme Gastroenterology and Hepatology Division of the Second Propedeutic Department of Internal Medicine Hippokration General HospitalMedical SchoolAristotle University of ThessalonikiThessaloniki 54642Greece

non-alcoholic fatty liver disease(NAFLD)is one of the leading causes of chronic liver disease,cirrhosis,and hepatocellular carcinoma worldwide,with an estimated prevalence of 25%.Post-liver transplantation(LT)recurrent or de novo hepatic steatosis is a common complication in recipients,irrespective of transplantation *** factors for graft steatosis mainly include obesity,immunosuppression,donor steatosis,and genetic *** transplant recipients are at high risk of developing insulin resistance,new-onset diabetes,and posttransplantation metabolic syndrome that is highly associated with immunosuppressive ***-LT NAFLD is often underdiagnosed due to the poor sensitivity of most routine imaging *** gold standard for the diagnosis of hepatic steatosis is liver biopsy,which is,however,limited to more complex cases due to its invasive *** is no approved pharmacotherapy in *** modification remains the cornerstone in NAFLD *** treatment strategies in post-LT NAFLD include lifestyle modifications,pharmacotherapy,bariatric surgery,and tailored ***,these approaches originate from recommendations in the general population,as there is scarce data regarding the safety and efficacy of current management strategies for NAFLD in liver transplant *** prospective studies are required to achieve tailored treatment for these patients.

关键词： non-alcoholic fatty liver disease Steatohepatitis Hepatic steatosis liver transplantation Cirrhosis Metabolic syndrome

Prevalence of non-alcoholic fatty liver disease in patients with nephrotic syndrome:A population-based study

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Hepatology 2023年第2期15卷 265-273页

作者： Somtochukwu Stephen Onwuzo Asif Ali Hitawala Antoine Boustany Prabhat Kumar Ashraf Almomani Chidera Onwuzo Jessy Mascarenhas Monteiro Imad Asaad Internal Medicine Cleveland Clinic FoundationClevelandOH 44111United States Digestive disease and Hepatology Cleveland Clinic Foundation FloridaWestonFI 33331United States Department of Medicine&Surgery General Hospital Lagos IslandLagos Island 101223LagosNigeria Department of Medicine Ross University School of MedicineBridgetown B11093St MichaelBarbados Digestive disease and Hepatology Cleveland Clinic FoundationClevelandOH 44111United States

BACKGROUND non-alcoholic fatty liver disease(NAFLD) is a global health concern with a prevalence of about 25% amongst United States adults. Its increased prevalence is attributed to increase in patients with obesity and metabolic syndrome, partly due to similar mechanisms of injury. Nephrotic syndrome(NS) is a clinical entity resulting from extensive proteinuria leading to hypoalbuminemia, hyperlipidemia, edema, and other complications. Given its association with hyperlipidemia, there is concern that patients with NS may be at increased risk of *** To perform a cross-sectional population-based study to investigate the prevalence and risk factors of NAFLD in patients with *** A large multicenter database(Explorys Inc., Cleveland, OH, United States) was utilized for this retrospective cohort study. A cohort of 49700 patients with a diagnosis of “non-alcoholic fatty liver disease” using the Systematized Nomenclature of Medicine-Clinical Terms(SNOMED-CT) between 1999-2022 was identified. Inclusion criteria were age ≥ 18 years, presence of NAFLD, presence of NS. There were no specific exclusion criteria. Univariate and multivariate analysis were performed to adjust for multiple risk factors including age, gender, Caucasian race, NS, type Ⅱ diabetes mellitus, hypothyroidism, dyslipidemia, obesity, metabolic syndrome and chronic kidney disease. Statistical analysis was conducted using R, and for all analyses, a 2-sided P value of disease were 14.84 [95% confidence interval(95%CI) 13.67-16.10], 17.05(95%CI 16.78-17.32), 6.99(95%CI 6.87-7.11), 13.61(95%CI 13.38-13.84), 19.19(95%CI 18.89-19.50), 29.09(95%CI 28.26--29.95), and 9.05(95

关键词： non-alcoholic fatty liver disease Nephrotic syndrome Chronic kidney disease Hyperlipidemia Population-based study Database

Transcriptome changes in stages of non-alcoholic fatty liver disease

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Hepatology 2022年第7期14卷 1382-1397页

作者： Jihad Aljabban Michael Rohr Saad Syed Kamal Khorfan Vincent Borkowski Hisham Aljabban Michael Segal Mohamed Mukhtar Mohammed Mohammed Maryam Panahiazar Dexter Hadley Ryan Spengler Erin Spengler Department of Medicine University of Wisconsin Hospital and ClinicsMadisonWI 53792United States Department of Medicine University of Central Florida College of MedicineOrlandoFL 32827United States Department of Medicine Northwestern Memorial HospitalChicagoIL 60611United States Department of Gastroenterology and Hepatology University of California San Francisco-FresnoFresnoCA 93701United States Department of Medicine Barry UniversityMiamiFL 33161United States Department of Medicine Michigan State University College of Human MedicineEast LansingMI 49503United States Department of Medicine Windsor University School of MedicineSaint Kitts 1621CayonSaint Kitts and Nevis Department of Surgery University of California San FranciscoSan FranciscoCA 94305United States Department of Artificial Intelligence PathologyUniversity of Central Florida College of MedicineOrlandoFL 32827United States Department of Gastroenterology and Hepatology University of Wisconsin Hospital and ClinicsMadisonWI 53792United States

BACKGROUND non-alcoholic fatty liver disease(NAFLD)is the most common chronic liver disease in the United States and *** currently understood model of pathogenesis consists of a‘multiple hit’hypothesis in which environmental and genetic factors contribute to hepatic inflammation and *** To examine the genetic expression of NAFLD and non-alcoholic steatohepatitis(NASH)tissue samples to identify common pathways that contribute to NAFLD and NASH *** We employed the Search Tag Analyze Resource for Gene Expression Omnibus platform to search the The National Center for Biotechnology Information Gene Expression Omnibus to elucidate NAFLD and NASH *** NAFLD,we conducted meta-analysis of data from 58 NAFLD liver biopsies and 60 healthy liver biopsies;for NASH,we analyzed 187 NASH liver biopsies and 154 healthy liver *** Our results from the NAFLD analysis reinforce the role of altered metabolism,inflammation,and cell survival in pathogenesis and support recently described contributors to disease activity,such as altered androgen and long non-coding RNA *** top upstream regulator was found to be sterol regulatory element binding transcription factor 1(SREBF1),a transcription factor involved in lipid *** of SREBF1,we observed upregulation in CXCL10,HMGCR,HMGCS1,fatty acid binding protein 5,paternally expressed imprinted gene 10,and downregulation of sex hormone-binding globulin and insulin-like growth factor *** molecular changes reflect low-grade inflammation secondary to accumulation of fatty acids in the *** results from the NASH analysis emphasized the role of cholesterol in *** canonical pathways,disease networks,and disease functions were related to cholesterol synthesis,lipid metabolism,adipogenesis,and metabolic *** upstream regulators included proinflammatory cytokines tumor necrosis factor and IL1B,PDGF BB,and *** of beta-estradiol

关键词： non-alcoholic fatty liver disease non-alcoholic steatohepatitis Bioinformatics AKT inhibitor Therapy

Associations between irritable bowel syndrome and non-alcoholic fatty liver disease:A systematic review

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Hepatology 2023年第7期15卷 925-938页

作者： Jareth Jun Jie Ng Wai Mun Loo Kewin Tien Ho Siah Yong Loo Lin School of Medicine National University of SingaporeSingapore 117597Singapore AliveoMedical Mount Alvernia and Mount Elizabeth HospitalsSingapore 574623Singapore Department of Medicine National University HospitalSingapore 119228Singapore

BACKGROUND Irritable bowel syndrome(IBS)is associated with obesity and metabolic *** and non-alcoholic fatty liver disease(NAFLD)are highly prevalent entities worldwide and may share similar mechanisms including gut dysbiosis,impaired intestinal mucosal barrier and immune system *** To systematically review their association according to the Preferred Reporting Items for Systemic Review and Meta-analyses *** PubMed,EMBASE and Cochrane Database of Systematic Reviews were searched for relevant *** searches were also *** Six studies were *** IBS and NAFLD subjects had significantly more metabolic risk factors like hypertension,obesity,dyslipidaemia and *** review showed that 23.2%to 29.4%of NAFLD patients had *** was significantly higher in NAFLD patients compared with patients without NAFLD(23.2%vs 12.5%,Pnon-IBS patients(P<0.001).Two studies showed a significant correlation between the severity of IBS and *** proportion of NAFLD subjects with IBS increased with NAFLD *** Further prospective studies are warranted to evaluate the relationship and shared pathways between IBS and NAFLD,potentially leading to the development of future therapeutics.

关键词： Irritable bowel syndrome Functional gastrointestinal disorder non-alcoholic fatty liver disease non-alcoholic steatohepatitis Gut dysbiosis Metabolic syndrome

non-alcoholic fatty liver disease later diagnosed as myotonic dystrophy

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Hepatology 2020年第9期12卷 685-692页

作者： Naoki Tanaka Takefumi Kimura Naoyuki Fujimori Yasuyuki Ichise Kenji Sano Akira Horiuchi Department of Metabolic Regulation Shinshu University School of MedicineMatsumoto 390-8621Japan Department of Gastroenterology Shinshu University School of MedicineMatsumoto 390-8621Japan Digestive disease Center Showa Inan General HospitalKomagane 399-4117Japan Department of Pathology Iida Municipal HospitalIida 395-8502Japan

BACKGROUND Myotonic dystrophy(MD)is sometimes accompanied by metabolic/endocrine disorders,including dyslipidemia,central obesity,and *** to considerable individual differences in the severity and progression of myopathy,MD patients with minimal-to-mild muscle symptoms might be followed as having other diseases,such as non-alcoholic fatty liver disease(NAFLD).CASE SUMMARY A 40-year-old non-obese man without a history of regular ethanol consumption was referred to our hospital due to persistent liver dysfunction and *** body mass index was 23.4 kg/*** histology demonstrated macrovesicular steatosis,ballooned hepatocytes with eosinophilic inclusion bodies,and perisinusoidal fibrosis,leading to the diagnosis of nonalcoholic steatohepatitis(NASH).Although he had no discernable muscle pain or weakness,persistently high serum creatine kinase(CK)and myoglobin levels as well as the presence of frontal baldness,a hatched face,history of cataract surgery,and grip myotonia indicated the possibility of *** blotting of the patient’s DNA revealed the presence of CTG repeats,confirming the *** When gastroenterologists encounter NAFLD/NASH patients,serum CK should be *** hyperCKemia,frontal baldness,a hatched face,history of cataract surgery,and grip myotonia are noted,the possibility of MD may be considered.

关键词： non-alcoholic fatty liver disease non-alcoholic steatohepatitis Frontal baldness Cataract Creatine kinase

non-alcoholic fatty liver disease:An expanded review

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Hepatology 2017年第16期9卷 715-732页

作者： Mark Benedict Xuchen Zhang Department of Pathology Yale University School of MedicineNew HavenCT 06510United States

non-alcoholic fatty liver disease(NAFLD) encompasses the simple steatosis to more progressive steatosis with associated hepatitis, fibrosis, cirrhosis, and in some cases hepatocellular carcinoma. NAFLD is a growing epidemic, not only in the United States, but worldwide in part due to obesity and insulin resistance leading to liver accumulation of triglycerides and free fatty acids. Numerous risk factors for the development of NAFLD have been espoused with most having some form of metabolic derangement or insulin resistance at the core of its pathophysiology. NAFLD patients are at increased risk of liver-related as well as cardiovascular mortality, and NAFLD is rapidly becoming the leading indication for liver transplantation. liver biopsy remains the gold standard for definitive diagnosis, but the development of noninvasive advanced imaging, biochemical and genetic tests will no doubt provide future clinicians with a great deal of information and opportunity for enhanced understanding of the pathogenesis and targeted treatment. As it currently stands several medications/supplements are being used in the treatment of NAFLD; however, none seem to be the "magic bullet" in curtailing this growing problem yet. In this review we summarized the current knowledge of NAFLD epidemiology, risk factors, diagnosis, pathogenesis, pathologic changes, natural history, and treatment in order to aid in further understanding this disease and better managing NAFLD patients.

关键词： non-alcoholic fatty liver disease Metabolic syndrome Steatohepatitis Hepatocellular carcinoma Steatosis

Prevalence of sarcopenia using different methods in patients with non-alcoholic fatty liver disease

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Hepatology 2022年第8期14卷 1643-1651页

作者： Naiade Silveira Almeida Raquel Rocha Claudineia Almeida de Souza Ana Carolina Sirelli da Cruz Bruna dos Reis Ribeiro Luiza Valois Vieira Carla Daltro Rafael Silva Manoel Sarno Helma Pinchemel Cotrim Programa de Pós-Graduação em Medicina e Saúde Universidade Federal da BahiaSalvador 40110-060BABrazil Departamento de Ciência da Nutrição Escola de NutriçãoUniversidade Federal da BahiaSalvador 40110-060Brazil Caliper Clínica e Escola de Imagem Salvador 41810-012Brazil

BACKGROUND Sarcopenia is a clinical condition associated with several liver diseases and it includes non-alcoholic fatty liver disease(NAFLD)in its broad spectrum as steatosis,steatohepatitis and ***,the criteria to define sarcopenia are diverse,and even those established in consensus have been discussed regarding their performance in making an accurate *** To evaluate the prevalence of sarcopenia,using different methods,in patients with NAFLD,and its association with clinical-anthropometric *** This was an observational study of outpatients with *** was defined by the European Working Group Consensus on Sarcopenia in Older People of 2010(EWGSOP1)and 2018(EWGSOP2).The skeletal muscle index was used to estimate muscle mass,handgrip strength was assessed using the dynamometer and physical performance by walking a distance of four meters at usual walking *** non-invasive fibrosis scores,fibrosis-4(FIB-4)index and Aspartate aminotransferase to platelet ratio index(APRI),were used to assess the absence and presence of *** Fifty-seven individuals with NAFLD were evaluated,the mean age(SD)was 52.7(11.3)years and 75.4%were *** assessed by FIB-4 and APRI was observed in 3.7%and 16.6%of patients with NAFLD,*** diagnosis of sarcopenia was identified only by EWGSOP1 in 3.5%of NAFLD patients,and the prevalence of probable/pre-sarcopenia was higher using the EWGSOP2 consensus at 26.3%,when compared to 1.8%with *** defined by EWGSOP1,was associated with grade I steatosis,but without overweight(P0.05).EWGSOP2 showed a greater number of patients with probable sarcopenia,and who were overweight(12(80.0%)),with a higher degree of steatosis[11(73.3%)and presence of fibrosis(1(6.7%),FIB-4 and 3(20.0%),APRI]compared to EWGSOP1[1(100%),0(0.0%),0(0.0%),FIB-4 and 0(0.0%),APRI,respectively].CONCLUSION The presen

关键词： non-alcoholic fatty liver disease Sarcopenia Muscle strength Physical performance liver fibrosis